FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2585408073> ?p ?o ?g. }

• W2585408073 endingPage "40263" @default.
• W2585408073 startingPage "40246" @default.
• W2585408073 abstract "// Ching-Yuan Wu 1, 2 , Yao-Hsu Yang 1, 2 , Yin-Yin Lin 1 , Feng-Che Kuan 3 , Yu-Shin Lin 4 , Wei-Yu Lin 5, 6 , Ming-Yen Tsai 7 , Jia-Jing Yang 1 , Yu-Ching Cheng 1 , Li-Hsin Shu 1 , Ming-Chu Lu 3 , Yun-Ju Chen 8, 9 , Kuan-Der Lee 2 and Hong-Yo Kang 8, 9 1 Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan 2 School of Chinese medicine, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan 3 Department of Hematology and oncology, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan 4 Department of Pharmacy, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan 5 Department of Urology, Chang Gung Memorial Hospital at Chiayi, Puzi City, Taiwan 6 Chang Gung University of Science and Technology, Chia-Yi, Taiwan 7 Department of Chinese Medicine, Chang Gung Memorial Hospital-Kaohsiung Medical Center, Kaohsiung, Taiwan 8 Graduate Institute of Clinical Medical Sciences, Chang Gung University, College of Medicine, Kaohsiung, Taiwan 9 Hormone Research Center, Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung, Taiwan Correspondence to: Kuan-Der Lee, email: kdlee@cgmh.org.tw Hong-Yo Kang, email: hkang3@mail.cgu.edu.tw Keywords: dihydroisotanshinone I, STAT3, prostate cancer, Skp2, CCL2 Received: May 10, 2016     Accepted: January 10, 2017     Published: February 01, 2017 ABSTRACT Danshen (Salvia miltiorrhiza Bunge) is widely used in traditional Chinese medicine. In our study, the in vivo protective effect of danshen in prostate cancer patients was validated through data from the National Health Insurance Research Database in Taiwan. In vitro , we discovered that dihydroisotanshinone I (DT), a bioactive compound present in danshen, can inhibit the migration of both androgen-dependent and androgen-independent prostate cancer cells. In addition, we noted that DT substantially inhibited the migratory ability of prostate cancer cells in both a macrophage-conditioned medium and macrophage/prostate cancer coculture medium. Mechanistically, DT both diminished the ability of prostate cancer cells to recruit macrophages and reduced the secretion of chemokine (C-C motif) ligand 2 (CCL2) from both macrophages and prostate cancer cells in a dose-dependent manner. Moreover, DT inhibited the protein expression of p-STAT3 and decreased the translocation of STAT3 into nuclear chromatin. DT also suppressed the expression of tumor epithelial–mesenchymal transition genes, including RhoA and SNAI1. In conclusion, danshen can prolong the survival rate of prostate cancer patients in Taiwan. Furthermore, DT can inhibit the migration of prostate cancer cells by interrupting the crosstalk between prostate cancer cells and macrophages via the inhibition of the CCL2/STAT3 axis. These results may provide the basis for a new therapeutic approach toward the treatment of prostate cancer progression." @default.
• W2585408073 created "2017-02-10" @default.
• W2585408073 creator A5006768945 @default.
• W2585408073 creator A5012200456 @default.
• W2585408073 creator A5013386212 @default.
• W2585408073 creator A5018773616 @default.
• W2585408073 creator A5047703113 @default.
• W2585408073 creator A5052724941 @default.
• W2585408073 creator A5053297767 @default.
• W2585408073 creator A5053469494 @default.
• W2585408073 creator A5057593261 @default.
• W2585408073 creator A5068498563 @default.
• W2585408073 creator A5071661539 @default.
• W2585408073 creator A5084867397 @default.
• W2585408073 creator A5086463632 @default.
• W2585408073 creator A5088581766 @default.
• W2585408073 date "2017-02-01" @default.
• W2585408073 modified "2023-10-02" @default.
• W2585408073 title "Anti-cancer effect of danshen and dihydroisotanshinone I on prostate cancer: targeting the crosstalk between macrophages and cancer cells via inhibition of the STAT3/CCL2 signaling pathway" @default.
• W2585408073 cites W1480357432 @default.
• W2585408073 cites W1483092292 @default.
• W2585408073 cites W1841767566 @default.
• W2585408073 cites W1896987049 @default.
• W2585408073 cites W1926376253 @default.
• W2585408073 cites W1929863302 @default.
• W2585408073 cites W1950741790 @default.
• W2585408073 cites W1964119246 @default.
• W2585408073 cites W1967332266 @default.
• W2585408073 cites W1968594028 @default.
• W2585408073 cites W1978960711 @default.
• W2585408073 cites W1979369138 @default.
• W2585408073 cites W1983180112 @default.
• W2585408073 cites W1983470102 @default.
• W2585408073 cites W1985454650 @default.
• W2585408073 cites W1990116192 @default.
• W2585408073 cites W1992224451 @default.
• W2585408073 cites W1993169060 @default.
• W2585408073 cites W1994427703 @default.
• W2585408073 cites W2000377675 @default.
• W2585408073 cites W2008504821 @default.
• W2585408073 cites W2013748221 @default.
• W2585408073 cites W2014098577 @default.
• W2585408073 cites W2014556566 @default.
• W2585408073 cites W2016580965 @default.
• W2585408073 cites W2021815995 @default.
• W2585408073 cites W2025519885 @default.
• W2585408073 cites W2027587678 @default.
• W2585408073 cites W2028544780 @default.
• W2585408073 cites W2045261772 @default.
• W2585408073 cites W2052580925 @default.
• W2585408073 cites W2061177902 @default.
• W2585408073 cites W2063808705 @default.
• W2585408073 cites W2065501783 @default.
• W2585408073 cites W2070108701 @default.
• W2585408073 cites W2089520086 @default.
• W2585408073 cites W2090754742 @default.
• W2585408073 cites W2095873383 @default.
• W2585408073 cites W2107151134 @default.
• W2585408073 cites W2112248146 @default.
• W2585408073 cites W2116836111 @default.
• W2585408073 cites W2127877679 @default.
• W2585408073 cites W2135363794 @default.
• W2585408073 cites W2136466466 @default.
• W2585408073 cites W2140411838 @default.
• W2585408073 cites W2160768910 @default.
• W2585408073 cites W2166873254 @default.
• W2585408073 cites W2167331614 @default.
• W2585408073 cites W2174136167 @default.
• W2585408073 cites W2175943024 @default.
• W2585408073 cites W2178881521 @default.
• W2585408073 cites W2194478316 @default.
• W2585408073 cites W2201282822 @default.
• W2585408073 cites W2265646490 @default.
• W2585408073 cites W2281046076 @default.
• W2585408073 cites W2286457890 @default.
• W2585408073 cites W2292939892 @default.
• W2585408073 cites W2293591396 @default.
• W2585408073 cites W2305049605 @default.
• W2585408073 cites W2411981799 @default.
• W2585408073 cites W2443762439 @default.
• W2585408073 cites W2474006646 @default.
• W2585408073 cites W2528762358 @default.
• W2585408073 cites W990755134 @default.
• W2585408073 doi "https://doi.org/10.18632/oncotarget.14958" @default.
• W2585408073 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5522253" @default.
• W2585408073 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28157698" @default.
• W2585408073 hasPublicationYear "2017" @default.
• W2585408073 type Work @default.
• W2585408073 sameAs 2585408073 @default.
• W2585408073 citedByCount "31" @default.
• W2585408073 countsByYear W25854080732017 @default.
• W2585408073 countsByYear W25854080732018 @default.
• W2585408073 countsByYear W25854080732019 @default.
• W2585408073 countsByYear W25854080732020 @default.
• W2585408073 countsByYear W25854080732021 @default.
• W2585408073 countsByYear W25854080732022 @default.
• W2585408073 countsByYear W25854080732023 @default.
• W2585408073 crossrefType "journal-article" @default.

• next